2 Stocks Down 13% and 34% to Buy Right Now

Group 1 - Broader equities have performed well in 2025, with the S&P 500 up 14% since the beginning of the year, despite earlier concerns about bear-market territory [1] - Merck and Fiverr International are highlighted as potential long-term winners despite their respective declines of 13% and 34% this year [2] Group 2 - Merck's Keytruda, a leading cancer therapy, is facing increased competition and a patent cliff in 2028, but it still generated third-quarter sales of $8.1 billion, up 10% year over year [4][5] - Merck's HPV vaccine sales are declining due to lower demand in China and Japan, but the company is well-equipped to handle these challenges [4] - Newer products like Winrevair and Capvaxive are showing promising sales, with Winrevair achieving $360 million in the third quarter and Capvaxive reporting $244 million [6] - Overall sales for Merck increased by 4% to $17.3 million, indicating resilience despite challenges in its HPV vaccine franchise [7] - The company's evolving core franchise and new product launches are expected to mitigate risks and drive future growth [8]